In experiments in mouse tissues and human cells, researchers say they have found that removing a membrane that lines the back of the eye may improve the success rate for regrowing nerve cells damaged ...

TORONTO and HAIFA, Israel, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a ...

NurExone Biologic Inc. has reported promising preclinical results for its drug ExoPTEN, which shows potential in repairing optic nerve damage and restoring vision, particularly for conditions like ...

BOSTON — There is a clear subset of pediatric patients with demyelinating disease who have substantial damage to the nerve layer in the retina but nevertheless have no vision loss, a new study shows. ...

NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ...

Researchers in Australia are claiming an important breakthrough in glaucoma research, demonstrating how the degenerative condition can be treated using an innovative form of gene therapy. The ...

NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ...

The regeneration of damaged neurons has been the ultimate goal for a large portion of neuroscience research. Understanding the underlying mechanisms that control neuronal growth is key to developing ...

Each year thousands of patients face life-long losses in sensation and motor function from spinal cord injury and related conditions in which axons are badly damaged or severed. New research in mice ...

When the axons that extend from neurons break during a spinal cord injury, the result is often a lifelong loss of motor functioning, because vital connections from the brain to other body parts cannot ...